Literature DB >> 22037483

Up-regulation of osteopontin expression by aryl hydrocarbon receptor via both ligand-dependent and ligand-independent pathways in lung cancer.

Cheng-Yen Chuang1, Han Chang, Pinpin Lin, Shih-Jung Sun, Po-Hung Chen, Yu-Ying Lin, Gwo-Tarng Sheu, Jiunn-Liang Ko, Shih-Lan Hsu, Jinghua Tsai Chang.   

Abstract

The secreted glycol-phosphoprotein OPN not only plays important roles in immune responses and tissue remodeling but is also intimately involved in tumorigenesis. It is up-regulated in various cancers and correlated with poor prognosis. It is evident by enhancing growth and migration of cancer cells. However, the mechanisms that participate in up-regulation of OPN in lung cancer are largely unknown. Up-regulation of aryl hydrocarbon receptor (AhR), a transcription factor activated by xenobiotics, has been observed in lung cancer as well as premalignant lesions. In this study we demonstrated that AhR positively regulates OPN expression in lung cancer. We observed positive correlation of OPN and AhR expression in lung cancer specimen. Knockdown or overexpression of AhR exhibited down- or up-regulation of OPN expression in lung cancer cells. We identified an OPN promoter region between positions -268 and +435 that was activated by both ligand-independent and ligand-activated AhR. However, this region does not contain AhR response element/dioxin response element (DRE/XRE). Further truncations and internal deletions of the promoter revealed that the ligand-independent and ligand-activated AhR function through different regions of OPN promoter. The region between -268 and -100 was required for ligand-independent AhR activity. This region contains several cis-elements including AP2, C/EBP, SP1 and AP1 sites. On the other hand, the ligand-activated AhR up-regulates OPN activity through two regions of OPN promoter; one contains NFκB site at +137 and the other is between positions -100 and +126. This study suggested that both overexpression of un-induced AhR (in cases of non-smokers with high level of AhR) and ligand-activated AhR (such as smokers) contribute to up-regulation of OPN that in turn leads to lung tumorigenesis.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22037483     DOI: 10.1016/j.gene.2011.10.019

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  15 in total

Review 1.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

Review 2.  Aryl hydrocarbon receptor ligands in cancer: friend and foe.

Authors:  Iain A Murray; Andrew D Patterson; Gary H Perdew
Journal:  Nat Rev Cancer       Date:  2014-12       Impact factor: 60.716

3.  Obesity and fatty liver are prevented by inhibition of the aryl hydrocarbon receptor in both female and male mice.

Authors:  Benjamin J Moyer; Itzel Y Rojas; Joanna S Kerley-Hamilton; Krishnamurthy V Nemani; Heidi W Trask; Carol S Ringelberg; Barjor Gimi; Eugene Demidenko; Craig R Tomlinson
Journal:  Nutr Res       Date:  2017-06-28       Impact factor: 3.315

4.  Aryl hydrocarbon receptor activation-mediated vascular toxicity of ambient fine particulate matter: contribution of polycyclic aromatic hydrocarbons and osteopontin as a biomarker.

Authors:  Chia-Chi Ho; Wei-Te Wu; Yi-Jun Lin; Chen-Yi Weng; Ming-Hsien Tsai; Hui-Ti Tsai; Yu-Cheng Chen; Shaw-Fang Yet; Pinpin Lin
Journal:  Part Fibre Toxicol       Date:  2022-06-23       Impact factor: 9.112

Review 5.  Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target.

Authors:  Stephen Safe; Syng-Ook Lee; Un-Ho Jin
Journal:  Toxicol Sci       Date:  2013-06-14       Impact factor: 4.849

Review 6.  Aryl hydrocarbon receptor and lung cancer.

Authors:  Junchieh J Tsay; Kam-Meng Tchou-Wong; Alissa K Greenberg; Harvey Pass; William N Rom
Journal:  Anticancer Res       Date:  2013-04       Impact factor: 2.480

7.  Prognostic value of secreted phosphoprotein-1 in pleural effusion associated with non-small cell lung cancer.

Authors:  He Zhang; Hong-bing Liu; Dong-mei Yuan; Zhao-feng Wang; Yun-fen Wang; Yong Song
Journal:  BMC Cancer       Date:  2014-04-23       Impact factor: 4.430

8.  Higher Matrix Stiffness Upregulates Osteopontin Expression in Hepatocellular Carcinoma Cells Mediated by Integrin β1/GSK3β/β-Catenin Signaling Pathway.

Authors:  Yang You; Qiongdan Zheng; Yinying Dong; Yaohui Wang; Lan Zhang; Tongchun Xue; Xiaoying Xie; Chao Hu; Zhiming Wang; Rongxin Chen; Yanhong Wang; Jiefeng Cui; Zhenggang Ren
Journal:  PLoS One       Date:  2015-08-17       Impact factor: 3.240

9.  Functional divergence and convergence between the transcript network and gene network in lung adenocarcinoma.

Authors:  Min-Kung Hsu; Chia-Lin Pan; Feng-Chi Chen
Journal:  Onco Targets Ther       Date:  2016-01-14       Impact factor: 4.147

10.  The association between osteopontin and survival in non-small-cell lung cancer patients: a meta-analysis of 13 cohorts.

Authors:  Ying Wang; Jin Yang; Hui Liu; Ji-Rui Bi; Ying Liu; Yan-Yan Chen; Ji-Yu Cao; You-Jin Lu
Journal:  Onco Targets Ther       Date:  2015-11-26       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.